Current and Emerging Therapies for Acute Graft-vs-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

Program Overview

Allogeneic HSCT is a revolutionary therapeutic discovery, yet despite advances, the procedure still carries substantial risk for complications and death. Even with prophylactic measures, many patients will go on to develop acute graft-versus-host disease (aGVHD). While there are several agents available for the prevention and treatment of aGVHD, there are still many unmet needs. In this Clinical Reflections® activity, learners will be presented with 2 cases of aGVHD and challenged by expert faculty to reflect back on how they could have been better managed. Faculty will then discuss current guidelines; prevention and treatment options; and emerging agents for prevention, first-line therapy, and steroid-refractory aGVHD.

Credit Expired
0.50 CE Credit(s)
Expires: September 22, 2023

Target Audience

Transplantation, hematology, and hematology/oncology clinicians engaged in the care of patients with GVHD.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Utilize available therapeutic strategies for the prevention and treatment of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (alloHSCT)
  • Implement current and emerging strategies to address unmet needs in the management of steroid-refractory acute GVHD in allogeneic HSCT

Activity Faculty


Doris M. Ponce, MD

Associate Professor, Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Doris M. Ponce, MD, has relevant financial relationships with Incyte Corporation, Kadmon Corporation (Advisor); CareDx, Ceramedix, Evive Biotech, Kadmon Corporation (Consultant); Incyte Corporation (Grant/Research Support).


Christine N. Duncan, MD

Assistant Professor, Pediatrics
Harvard Medical School
Medical Director, Clinical Research and Clinical Development
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, MA

Christine N. Duncan, MD, has relevant financial relationships with bluebird bio, Inc., Jazz Pharmaceuticals, Magenta Therapeutics, Novartis, Omeros, Tome Biosciences (Consultant).

Supporter Statement

This activity is supported by an independent medical education grant from CSL Behring LLC.

Provider Statement

This activity is provided by RMEI Medical Education, LLC

Disclosure of Financial Relationships


Planners and Managers

Method of Participation and Request for Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | | (866) 770-RMEI


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources